<DOC>
	<DOCNO>NCT00266162</DOCNO>
	<brief_summary>Eisenmenger 's syndrome present severe clinical picture polymorbidity constitute great burden individual well familial social level . The combination critically increase pulmonary vascular resistance , progressive pressure load right ventricle disturbance pulmonary gas exchange result long-term polymorbidity . The objective study look effect medium-term pulmonary pressure-lowering treatment oral bosentan patient congenital heart defect clinically relevant pulmonary arterial hypertension ( PAH ) , take advantage extensive diagnostic procedure .</brief_summary>
	<brief_title>Bosentan Treatment Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Eisenmenger 's syndrome present severe clinical picture polymorbidity constitute great burden individual well familial social level . The combination critically increase pulmonary vascular resistance , progressive pressure load right ventricle disturbance pulmonary gas exchange result long-term polymorbidity . While patient 's ability care him-/ get lose time , financial burden due need medical consultation hospital stay increase . This distress patient family . Usually , death result cardiac decompensation presence gradually increase pulmonary vascular resistance hypoxic lesion organ include myocardium ( Hopkins , AJC 2002 ) . With good understand pathophysiology underlie pulmonary hypertension , novel therapeutic approach develop past year . These include ) inhibition NO-cGMP-degrading type 5 phosphodiesterase ( PDE-5 ) b ) antagonise endothelin system ( Krum , Curr Opin Investig Drugs 2003 ) . The goal dilatation abnormally constrict pulmonary arterial vessel relaxation vascular smooth muscle cell reversal pulmonary vascular remodelling ( Ghofrani , Pneumologie 2002 ) . Specific drug affect pulmonary vascular resistance study . Intravenous prostacyclin major disadvantage : high cost , tachyphylaxis , risk infection rebound hypertension upon discontinuation . Inhalative pulmonary vasodilator , particular iloprost , may effective primary pulmonary hypertension ( Olschewski , Ann Int Med 1996 ; Hoeper , Pneumologie 2001 ) , administration time-consuming , due mode application effect intermittent , last 75 minute ( Hoeper , JACC 2000 ) . Considering , oral treatment appear preferable , easy administration , hence , good patient compliance . Bosentan ( Tracleer® ) non-selective endothelin receptor antagonist dual binding ( ETA ETB ) complete block endothelin-1 . It first drug class approve lower pulmonary vascular resistance . Significant effect haemodynamics exercise tolerance demonstrate monotherapy ( Galie , J Am Coll Cardiol 2003 ; Rubin , N Engl J Med 2002 ) add-on treatment inhalational parenteral prostanoids ( Hoeper , Eur Respir J 2003 ) . In child least 10 kg body weight , bosentan significantly improve pulomary haemodynamics , pharmacokinetics find comparable adult ( Bars , Clin Pharmacol Ther 2003 ) . Good long-term tolerability effectiveness period one year demonstrate ( Sitbon , Chest 2003 ) . Moreover , animal model increase pulmonary blood flow activation endothelin system absent bosentan treatment haemodynamic morphological change prevent . Available data suggest effect bosentan limit primary pulmonary hypertension . Further study require prove effectiveness pulmonary hypertension various aetiology . The objective study look effect medium-term pulmonary pressure-lowering treatment oral bosentan patient congenital heart defect clinically relevant pulmonary arterial hypertension ( PAH ) , take advantage extensive diagnostic procedure . The data obtain suppose contribute development guideline treatment PAH cause congenital heart defect . The data evaluate term health economics ( network subproject `` Health Economics '' , project manager : Prof. Dr. med . Karl W. Lauterbach ) . The hypothesis : 1 . Bosentan specifically improve pulomonary vascular damage cause hypercirculation . As immediate effect , block vasoconstriction , long run , revert pulmonary vascular remodelling . 2 . In patient Eisenmenger 's syndrome , result decrease pulmonary vascular resistance normalization pulmonary vascular responsiveness . 3 . This follow increase lung perfusion systemic oxygen supply . 4 . The patient benefit improvement his/her clinical condition exercise tolerance . These hypothesis test compare finding follow examination immediately 24-week treatment bosentan : clinical examination , ECG , echocardiography , CPX , MRT , cardiac catheterization pulmonary artery manometry , laboratory test . As secondary objective , degree concordance finding different invasive non-invasive examination diagnostic procedure investigate .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Nonspecific : Written inform consent obtain Specific : Age least 18 year Presence cyanosis &lt; 93 % arterial oxygen saturation ( measure transcutaneous pulse oximetry ) Clinical indication invasive diagnostic procedure plan study give ; evaluate basis observation , medicinal treatment ) Presence PAH diagnose invasive method Rp : Rs &gt; 0.75 measured rest , test pulmonary vasodilatory reserve One following diagnosis : noncorrected large congenital shunt defect atrial , ventricular arterial level : PAPVD , ASD , SVD , VSD , AVSD , TAC , APW , PDA , combination . Surgically correct shunt defect ( diagnosis ) significant residual defect Other diagnosis univentricular physiology/haemodynamics . Nonspecific : pregnancy lactation woman childbearing age sexually active without practise reliable method contraception disease impairment , opinion investigator , excludes subject participation substance abuse ( alcohol , medicine , drug ) medical , psychological social circumstance would adversely affect patient 's ability participate adequately study increase risk patient others case participation . insufficient compliance subject MRI perform ( contrast medium allergy , claustrophobia , cardiac pacemaker ) subject able perform CPX Specific : pulmonary hypertension aetiology specify inclusion criterion subject know intolerance NO iloprost constituent acute decompensated heart failure within 7 day invasive procedure haemodynamic instability would increase risk pulmonary arterial reactivity test arterial hypotension anaemia ( Hb &lt; 10 g/dl ) decompensated symptomatic polycythaemia thrombocytopenia ( &lt; 50,000/μl ) secondary impairment organic ( renal , hepatic ) function source pulmonary blood flow render measurement blood flow lung pulmonary vascular resistance impossible obstruction pulmonary blood outflow leave ventricular disease significant valvular disease tricuspid pulmonary regurgitation pericardial constriction history stroke , myocardial infarction lifethreatening arrhythmia within 6 month screen bronchopulmonary dysplasia chronic lung diseases history significant pulmonary embolism relevant disease ( e.g . HIV infection ) trisomy 21 Prohibited concomitant medication : Any medication list discontinue least 30 day prior screen . Unspecified significant medication ( e.g . medication diabetes immunosuppression ) Unstable medication , recent change dosage regimen Drugs treat pulmonary hypertension ( endothelin receptor antagonist , PDE5 antagonists , prostanoids . ( Specific pulmonary vasodilator cardiac catheterisation allow . ) Other medication vascular action Medication compatible bosentan interferes metabolism ( inhibitor CYP2C9 CYP3A4 ) , investigator 's opinion , may interfere bosentan treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Heart Defects , Congenital</keyword>
	<keyword>Eisenmenger Complex</keyword>
	<keyword>Hypertension , Pulmonary</keyword>
	<keyword>Pulmonary Heart Disease</keyword>
	<keyword>Pulmonary Circulation</keyword>
	<keyword>Vascular Resistance</keyword>
</DOC>